- 3x lower net revenue than experienced launchers
- $247M average launch cost
- 24-month prep timeline
- 78% of small-cap companies face delays or rejections
Solutions Shared:
- Strategies that are 25% more capital-efficient and 50% faster
- Real-world wins:
- Oncology company exceeded forecasts, while doubling profitability
- Biotech cut launch costs by 25%
- Iterum became launch-ready in 6 months
- Millions saved via flexible contracts
Looking to Learn More?
Our white paper, “Transformative Commercialization for New BioPharma Entrants: Ensuring Success with Capital and Time Efficiency,” outlines how EVERSANA’s model can level the playing field and drive success.
DOWNLOAD NOWAuthor
Anne Marie is helping EVERSANA deliver value to stakeholders across the life sciences industry. Through her multi-decade career at prominent large and small pharmaceutical companies, she has become a proven biopharma leader driving cross-functional…
Jennifer is the Executive Vice President of Complete Commercialization at EVERSANA, a leading provider of commercialization services to the life sciences industry. Her robust background includes more than two decades of market access strategies…
Maneesh comes to EVERSANA Management Consulting from IQVIA. He held a number of leadership roles over his 10 years at the firm, most recently serving as Practice Lead, Launch Excellence and Brand and Commercial…